Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Prelude Therapeutics Incorporated/ 10-Q

Quarterly Report · 10-Q

Prelude Therapeutics Incorporated

PRLDNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 11, 2026Accepted Aug 11, 2026, 8:05 AM EDTCIK 1678660Accession 0001193125-26-343475
View company →Permanent SEC source ↗
Share

Company context

Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline features highly selective KAT6A

Current securities

PRLDNASDAQ · EQUITY · Current

Recent company filings

  1. Regulation FD DisclosureSep 10, 2026
  2. Results of Operations and Financial ConditionAug 11, 2026
  3. SCHEDULE 13G - filed by Soleus Private Equity Fund III, L.P. regarding Prelude Therapeutics IncJul 8, 2026
  4. 4 filingJun 10, 2026
  5. 4 filingJun 10, 2026

Registered securities in this filing

PRELUDE THERAPEUTICS INC · 10-Q · Filed 2026-08-11

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001 per share

Symbol
PRLD
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: C_1c376dc2-80f6-496f-856b-907186580d25

Dimensions: Not supplied

Accession 000119312526343475 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.